Interactions of SARS-CoV-2 infection and genetic variation on the risk of cognitive decline and Alzheimer’s disease in Ancestral and Admixed Populations

这一计划中提出的科学利用了由 正在进行的冠状病毒大流行，以研究可定义的和有时间限制的风险诱导之间的相互作用 环境事件(接触病毒)和基因组变异对认知能力下降和 阿尔茨海默病和相关痴呆(ADRD)在来自代表性不足的大量老年人队列中的研究 美国的少数民族以及非洲和南美洲的祖先群体。领导该项目的调查人员 在指导国际财团和纵向队列方面有丰富的经验，包括创建 并对安第斯地区的一个美洲印第安人队列进行了十多年的跟踪调查。我们有飞行员 新招募的美洲印第安人血统老年人认知障碍终点的确定。这 U19将研究全基因组序列遗传变异与新冠肺炎的相互作用 感染和疾病对4,300人认知能力下降和ADRD风险的影响 在德克萨斯州、纽约州、华盛顿州、伊巴丹(尼日利亚)和Jujuy(阿根廷)招募队列。参与者 评估将包括神经、认知、成像和基于血液的生物标记物评估，使用 协调方案和3个时间点：感染后几个月内以及感染后18个月和36个月。 我们建议用3个高度集成的项目来回答这个复杂的研究问题，这些项目由EQUAL支持 综合行政、临床、神经成像和数据管理/统计核心。所有项目都涉及 包括加州大学在内的机构联盟内的综合多学科调查团队 德克萨斯健康圣安东尼奥，德克萨斯大学里奥格兰德山谷，华盛顿大学医学院， 阿尔伯特·爱因斯坦医学院，华盛顿大学，伊巴丹大学，卫生部 Jujuy省(阿根廷)和FULTRA基金会(阿根廷)。资源和研究专业知识将 在多个地点和核心之间紧密协调，并整合到国家老龄研究所 阿尔茨海默氏症测序项目和国家阿尔茨海默氏症协调中心将帮助确保 获得的数据和知识的最佳共享。

The science proposed in this program takes advantage of the unique scientific opportunity created by the ongoing coronavirus pandemic, to study the interaction between a definable and time-limited risk-inducing environmental event (exposure to the virus) and genomic variation on the occurrence of cognitive decline and Alzheimer’s disease and related dementias (ADRD) in large cohorts of older adults from underrepresented minorities in the USA and ancestral groups in Africa and South America. The investigators leading the program have extensive experience in directing international consortia and longitudinal cohorts, including the creation and follow up of an Amerindian cohort in the Andes region for longer than a decade. We have pilot ascertainment of cognitive impairment end-points in newly recruited older adults of Amerindian ancestry. This U19 will investigate the interactions between whole genome sequence genetic variations and COVID-19 infection and disease on the risk of cognitive decline and risk of ADRD in 4,300 individuals as part of newly recruited cohorts in Texas, New York, Washington State, Ibadan (Nigeria), and Jujuy (Argentina). Participant assessments will include neurological, cognitive, imaging and blood-based biomarker evaluations using harmonized protocols and at 3 time points: within a few months of infection and 18 and 36 months afterwards. We propose to answer this complex research question with 3 highly integrated Projects supported by equally integrated Administrative, Clinical, Neuroimaging and Data Management/Statistics Cores. All projects involve integrated multidisciplinary teams of investigators within a consortium of institutions including University of Texas Health San Antonio, University of Texas Rio Grande Valley, Washington University School of Medicine, Albert Einstein College of Medicine, University of Washington, University of Ibadan, the Ministry of Health of the Province of Jujuy (Argentina) and the FULTRA Foundation (Argentina). Resources and study expertise will be tightly coordinated across multiple sites and Cores, and integrated to the National Institute of Aging Alzheimer’s Disease Sequencing Project and National Alzheimer’s Coordinating Center which will help ensure optimal sharing of the acquire data and knowledge.